Anti-PD1 treatments are considered to be more favourable than anti-CTLA-4 treatments in certain tumour types due to their better safety and tolerability profiles, as well as having potential biomarkers for patient stratification and predictions for clinical outcome [6,13]. The gene discussed is CTLA4; the disease is neoplasm.